96 related articles for article (PubMed ID: 17891370)
1. [Cost considerations for whole-body MRI and PET/CT as part of oncologic staging].
Plathow C; Walz M; Lichy MP; Aschoff P; Pfannenberg C; Bock H; Eschmann SM; Claussen CD; Schlemmer HP
Radiologe; 2008 Apr; 48(4):384-96. PubMed ID: 17891370
[TBL] [Abstract][Full Text] [Related]
2. Equity in the distribution of CT and MRI in China: a panel analysis.
He D; Yu H; Chen Y
Int J Equity Health; 2013 Jun; 12():39. PubMed ID: 23742755
[TBL] [Abstract][Full Text] [Related]
3. Programmatic Implementation of a Custom Subspecialized Oncologic Imaging Workflow Manager at a Tertiary Cancer Center.
Becker AS; Das JP; Woo S; Elnajjar P; Chaim J; Erinjeri JP; Hricak H; Vargas HA
JCO Clin Cancer Inform; 2022 Sep; 6():e2200066. PubMed ID: 36084275
[TBL] [Abstract][Full Text] [Related]
4. The Role of Imaging in Health Screening: Screening for Specific Conditions.
Ballard DH; Burton KR; Lakomkin N; Kim S; Rajiah P; Patel MJ; Mazaheri P; Whitman GJ
Acad Radiol; 2021 Apr; 28(4):548-563. PubMed ID: 32404272
[TBL] [Abstract][Full Text] [Related]
5. Sino-German symposium on total-body PET/CT in theranostics.
Zhang M; Guo R; Wang H; Shi K; Weber WA; Li B
Eur J Nucl Med Mol Imaging; 2024 Jun; ():. PubMed ID: 38837059
[No Abstract] [Full Text] [Related]
6. Reply to: Balancing Cost and Efficiency in Screening Potential Organ Donors With Whole Body CT.
Mensink JW; Pol RA; Nijboer WN; de Vries KM; Alwayn IPJ; Braat AE
Transplant Direct; 2020 Nov; 6(11):e623. PubMed ID: 33134499
[No Abstract] [Full Text] [Related]
7. Robustness of apparent diffusion coefficient-based lymph node classification for diagnosis of prostate cancer metastasis.
Noto B; Eveslage M; Auf der Springe K; Exler A; Faldum A; Heindel W; Milachowski S; Roll W; Schäfers M; Stegger L; Bauer J
Eur Radiol; 2023 Dec; ():. PubMed ID: 38099965
[TBL] [Abstract][Full Text] [Related]
8. Indirect comparison of the diagnostic performance of
Hu X; Li D; Liang Z; Liao Y; Yang L; Wang R; Wang P; Cai J
BMC Cancer; 2021 Oct; 21(1):1080. PubMed ID: 34615498
[TBL] [Abstract][Full Text] [Related]
9. Emerging Role of Carotid MRI for Personalized Ischemic Stroke Risk Prediction in Patients With Carotid Artery Stenosis.
Nies KPH; Smits LJM; Kassem M; Nederkoorn PJ; van Oostenbrugge RJ; Kooi ME
Front Neurol; 2021; 12():718438. PubMed ID: 34413828
[TBL] [Abstract][Full Text] [Related]
10. Whole-body diffusion-weighted MRI in lymphoma-comparison of global apparent diffusion coefficient histogram parameters for differentiation of diseased nodes of lymphoma patients from normal lymph nodes of healthy individuals.
Donners R; Yiin RSZ; Koh DM; De Paepe K; Chau I; Chua S; Blackledge MD
Quant Imaging Med Surg; 2021 Aug; 11(8):3549-3561. PubMed ID: 34341730
[TBL] [Abstract][Full Text] [Related]
11. Staging of Primary Abdominal Lymphomas: Comparison of Whole-Body MRI with Diffusion-Weighted Imaging and (18)F-FDG-PET/CT.
Stecco A; Buemi F; Quagliozzi M; Lombardi M; Santagostino A; Sacchetti GM; Carriero A
Gastroenterol Res Pract; 2015; 2015():104794. PubMed ID: 26798331
[TBL] [Abstract][Full Text] [Related]
12. Comparison between whole-body MRI and Fluorine-18-Fluorodeoxyglucose PET or PET/CT in oncology: a systematic review.
Ciliberto M; Maggi F; Treglia G; Padovano F; Calandriello L; Giordano A; Bonomo L
Radiol Oncol; 2013 Jul; 47(3):206-18. PubMed ID: 24133384
[TBL] [Abstract][Full Text] [Related]
13. In vivo imaging of glucose uptake and metabolism in tumors.
Walker-Samuel S; Ramasawmy R; Torrealdea F; Rega M; Rajkumar V; Johnson SP; Richardson S; Gonçalves M; Parkes HG; Arstad E; Thomas DL; Pedley RB; Lythgoe MF; Golay X
Nat Med; 2013 Aug; 19(8):1067-72. PubMed ID: 23832090
[TBL] [Abstract][Full Text] [Related]
14. [Importance of whole body MRI for staging of colorectal cancer].
Schmidt G
Radiologe; 2012 Jun; 52(6):537-44. PubMed ID: 22618626
[TBL] [Abstract][Full Text] [Related]
15. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.
Schreiter NF; Brenner W; Nogami M; Buchert R; Huppertz A; Pape UF; Prasad V; Hamm B; Maurer MH
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):72-82. PubMed ID: 21927931
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner?
Langer A
BMC Health Serv Res; 2010 Oct; 10():283. PubMed ID: 20932288
[TBL] [Abstract][Full Text] [Related]
17. The uses and limitations of whole-body magnetic resonance imaging.
Schmidt G; Dinter D; Reiser MF; Schoenberg SO
Dtsch Arztebl Int; 2010 Jun; 107(22):383-9. PubMed ID: 20574553
[TBL] [Abstract][Full Text] [Related]
18. [Whole-body MRI and FDG-PET/CT imaging diagnostics in oncology].
Schmidt GP; Haug A; Reiser MF; Rist C
Radiologe; 2010 Apr; 50(4):329-38. PubMed ID: 20229091
[TBL] [Abstract][Full Text] [Related]
19. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis.
Kwee TC; Kwee RM
Eur Radiol; 2009 Mar; 19(3):731-44. PubMed ID: 18925401
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
